Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer
A Phase 2 Study of RO4929097 (NSC 749225) in Combination With FOLFOX Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Alone for the First-Line Treatment of Patients With Metastatic Colorectal Cancer (NCI #8467)
Status: Enrolling
Updated:  4/3/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer
A Phase 2 Study of RO4929097 (NSC 749225) in Combination With FOLFOX Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Alone for the First-Line Treatment of Patients With Metastatic Colorectal Cancer (NCI #8467)
Status: Enrolling
Updated: 4/3/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer
A Phase 2 Study of RO4929097 (NSC 749225) in Combination With FOLFOX Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Alone for the First-Line Treatment of Patients With Metastatic Colorectal Cancer (NCI #8467)
Status: Enrolling
Updated:  4/3/2017
The Mayo Clinic
mi
from
Rochester, MN
Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer
A Phase 2 Study of RO4929097 (NSC 749225) in Combination With FOLFOX Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Alone for the First-Line Treatment of Patients With Metastatic Colorectal Cancer (NCI #8467)
Status: Enrolling
Updated: 4/3/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer
A Phase 2 Study of RO4929097 (NSC 749225) in Combination With FOLFOX Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Alone for the First-Line Treatment of Patients With Metastatic Colorectal Cancer (NCI #8467)
Status: Enrolling
Updated:  4/3/2017
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer
A Phase 2 Study of RO4929097 (NSC 749225) in Combination With FOLFOX Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Alone for the First-Line Treatment of Patients With Metastatic Colorectal Cancer (NCI #8467)
Status: Enrolling
Updated: 4/3/2017
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/3/2017
University of California at Los Angeles Dept of Onc
mi
from
Los Angeles, CA
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/3/2017
University of California at Los Angeles Dept of Onc
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/3/2017
Memorial Sloan Kettering Cancer Center Oncology Dept
mi
from
NY, NY
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/3/2017
Memorial Sloan Kettering Cancer Center Oncology Dept
mi
from
NY, NY
Click here to add this to my saved trials
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/3/2017
Array BioPharma Investigative Site
mi
from
Leuven,
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/3/2017
Array BioPharma Investigative Site
mi
from
Leuven,
Click here to add this to my saved trials
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/3/2017
Stanford University
mi
from
Stanford, CA
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/3/2017
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/3/2017
University of Chicago
mi
from
Chicago, IL
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/3/2017
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/3/2017
Johns Hopkins University
mi
from
Baltimore, MD
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/3/2017
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/3/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/3/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/3/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/3/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/3/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/3/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/3/2017
Providence Oncology & Hematology Care Eastside
mi
from
Portland, OR
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/3/2017
Providence Oncology & Hematology Care Eastside
mi
from
Portland, OR
Click here to add this to my saved trials
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/3/2017
UPMC Cancer Center
mi
from
Pittsburgh, PA
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/3/2017
UPMC Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/3/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/3/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Plasma ctDNA in Patients Undergoing Diagnostic Colonoscopy
Determination of the Utility of Plasma Circulating Tumor DNA (ctDNA) Measurements for the Detection of Colon Cancer in Patients Undergoing Diagnostic Colonoscopy
Status: Enrolling
Updated:  4/3/2017
Pathway Genomics
mi
from
San Diego, CA
Plasma ctDNA in Patients Undergoing Diagnostic Colonoscopy
Determination of the Utility of Plasma Circulating Tumor DNA (ctDNA) Measurements for the Detection of Colon Cancer in Patients Undergoing Diagnostic Colonoscopy
Status: Enrolling
Updated: 4/3/2017
Pathway Genomics
mi
from
San Diego, CA
Click here to add this to my saved trials
Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors
Worry, Uncertainty and Insomnia: A Cognitive-behavioral Intervention for Cancer Survivors
Status: Enrolling
Updated:  4/4/2017
Wexner Medical Center at The Ohio State University Department of Psychiatry
mi
from
Columbus, OH
Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors
Worry, Uncertainty and Insomnia: A Cognitive-behavioral Intervention for Cancer Survivors
Status: Enrolling
Updated: 4/4/2017
Wexner Medical Center at The Ohio State University Department of Psychiatry
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer
A Phase I Study of Guanylyl Cyclase C (GCC)-Encoding Replication-Deficient Human Type 5 Recombinant Adenovirus Vaccine (Ad5-hGCC-PADRE) in Stage I and II Colon Cancer Patients
Status: Enrolling
Updated:  4/4/2017
Thomas Jefferson University
mi
from
Philadelphia, PA
Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer
A Phase I Study of Guanylyl Cyclase C (GCC)-Encoding Replication-Deficient Human Type 5 Recombinant Adenovirus Vaccine (Ad5-hGCC-PADRE) in Stage I and II Colon Cancer Patients
Status: Enrolling
Updated: 4/4/2017
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care
Adherence to NCCN Survivorship Care Guidelines in Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care
Status: Enrolling
Updated:  4/5/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care
Adherence to NCCN Survivorship Care Guidelines in Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care
Status: Enrolling
Updated: 4/5/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Understanding the Value of Community Vital Signs in Primary Care
Understanding the Value of Community Vital Signs in Primary Care
Status: Enrolling
Updated:  4/11/2017
Fairfax Family Practice Centers
mi
from
Fairfax, VA
Understanding the Value of Community Vital Signs in Primary Care
Understanding the Value of Community Vital Signs in Primary Care
Status: Enrolling
Updated: 4/11/2017
Fairfax Family Practice Centers
mi
from
Fairfax, VA
Click here to add this to my saved trials
Understanding the Value of Community Vital Signs in Primary Care
Understanding the Value of Community Vital Signs in Primary Care
Status: Enrolling
Updated:  4/11/2017
Virginia Ambulatory Care Outcomes Research Network
mi
from
Richmond, VA
Understanding the Value of Community Vital Signs in Primary Care
Understanding the Value of Community Vital Signs in Primary Care
Status: Enrolling
Updated: 4/11/2017
Virginia Ambulatory Care Outcomes Research Network
mi
from
Richmond, VA
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Anniston, AL
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Anniston, AL
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Birmingham, AL
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Casa Grande, AZ
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Casa Grande, AZ
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Tucson, AZ
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Hot Springs, AR
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Hot Springs, AR
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Palm Springs, CA
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Palm Springs, CA
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
San Diego, CA
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Fairfield, CT
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Fairfield, CT
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Stamford, CT
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Stamford, CT
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Bay Pines, FL
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Bay Pines, FL
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Fort Meyers, FL
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Fort Meyers, FL
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Port St Lucie, FL
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Port St Lucie, FL
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Port St. Lucie, FL
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Port St. Lucie, FL
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Galesburg, IL
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Galesburg, IL
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Park Ridge, IL
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Park Ridge, IL
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Quincy, IL
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Quincy, IL
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Research Site
mi
from
Layfayette, IN
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Research Site
mi
from
Layfayette, IN
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
New Albany, IN
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
New Albany, IN
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Alexandria, LA
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Alexandria, LA
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Research Site
mi
from
Layfayette, LA
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Research Site
mi
from
Layfayette, LA
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Hagerstown, MD
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Hagerstown, MD
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Ann Arbor, MI
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Ypsilanti, MI
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Ypsilanti, MI
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
St Louis, MO
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
St Louis, MO
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Great Falls, MT
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Great Falls, MT
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Lincoln, NE
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Lincoln, NE
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Summit, NJ
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Summit, NJ
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Fresh Meadows, NY
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Fresh Meadows, NY
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Northport, NY
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Northport, NY
Click here to add this to my saved trials